AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00668434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will look the same as the study medication but will not contain active medicine.
Trial: NCT04238663
Drug: EU approved Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Trial: NCT04238663
Drug: US licenced Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Trial: NCT03596177
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
Trial: NCT04050592
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
Trial: NCT03596177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
Trial: NCT03184909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules of look alike inert substance for control
Trial: NCT00406575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
Trial: NCT03790982
Drug: Placebo of AD-35 60mg /AD-35 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
Trial: NCT03790982
Drug: Placebo of AD-35 60mg /AD-35 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
Trial: NCT01921257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02362711
Drug: NPC-16 Standard Dosing Regimen Group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02362711
Drug: NPC-16 Continuous Dosing Regimen Group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02362711
Drug: Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01061515
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01734941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092040
Drug: Comparator: risedronate / Duration of Intervention: 12 mo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01073527
Drug: hypertonic saline-salbutamol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypertonic saline 5% with 0.5cc salbutamol
Trial: NCT00683579
Drug: Early Treatment with HAART
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART with possibility of de-intensification
Trial: NCT00683579
Drug: HAART Treatment - standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA \>100,000 copies/ml
Trial: NCT02199886
Drug: BIBH 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labeled with eight to ten millicurie of 131I
Trial: NCT03790982
Drug: AD-35 30 mg + Placebo of AD-35 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
Trial: NCT01699594
Drug: Methacholine Chloride
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
Trial: NCT02167633
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
Trial: NCT04376541
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: amount of fentanyl used in both groups
Trial: NCT01605071
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo
Trial: NCT02401750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matches both experimental drugs
Trial: NCT00624572
Drug: chlorexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorexidine gel 1% during 7 days inside root canals
Trial: NCT03811223
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection every 2 weeks for 12 weeks
Trial: NCT01294735
Drug: MK-4827
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
Trial: NCT02874690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill identical in appearance to methylphenidate
Trial: NCT01670513
Drug: IDP-118 Low Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks
Trial: NCT00648076
Drug: Depakote ER® Tablets 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, single dose fed
Trial: NCT04344405
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control
Trial: NCT00436566
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00032019
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
Trial: NCT00032019
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
Trial: NCT04504032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
Trial: NCT01504854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
Trial: NCT00578864
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes
Trial: NCT00578864
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 3 and 5 with doxorubicin
Trial: NCT00578864
Drug: Hematopoietic Factor
RxNorm normalized name: Hematopoietic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
Trial: NCT00771459
Drug: Isotonic NaCl
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia
Trial: NCT00210015
Drug: INS37217 Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183025
Drug: Meloxicam 15 mg
RxNorm normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183025
Drug: Placebo matching 7.5 mg meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183025
Drug: Placebo matching 15 mg meloxicam
RxNorm normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183025
Drug: Placebo matching 500 mg mefenamic acid
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191202
Drug: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01729403
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally daily, 16 weeks
Trial: NCT00745485
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03969901
Drug: IMI/REL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 2 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
Trial: NCT01667575
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic of the quadruple therapy
Trial: NCT03560193
Drug: 5%Povidone Iodine- 69%Ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
Trial: NCT02039180
Drug: AZD3293 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
Trial: NCT02039180
Drug: AZD3293 tablet formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
Trial: NCT00816907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 placebo capsules taken twice daily for 16 weeks
Trial: NCT02040194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for intratympanic injection
Trial: NCT00633438
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
Trial: NCT00016523
Drug: Inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Started at 5 ppm and could be increased to 10 ppm
Trial: NCT00016523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Started at 5 ppm and could be increased to 10 ppm
Trial: NCT02571192
Drug: SHP626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
Trial: NCT01665417
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib: 125mg, oral administration, three times per day.
Trial: NCT01665417
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
Trial: NCT01665417
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
Trial: NCT02198287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00347711
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01433458
Drug: RLX030A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLX030 is administered as a continuous 24 hour infusion
Trial: NCT04356755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
Trial: NCT01787526
Drug: oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets of 100mg iron over 8 weeks, total dose 10g
Trial: NCT04081844
Drug: HCP1306
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
Trial: NCT04081844
Drug: HGP0904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 5mg(Norvasc)
Trial: NCT04081844
Drug: HGP0608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100mg(Cozaar)
Trial: NCT02802059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).
Trial: NCT01661400
Drug: Metronomic Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00243230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three tablets of placebo once daily for 48 weeks.
Trial: NCT00243230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of placebo once daily for 48 weeks.
Trial: NCT02834676
Drug: Gelified Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
Trial: NCT01916122
Drug: Fluorestradiol (FES)
RxNorm normalized name: fluoroestradiol (18F)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03393364
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive ketorolac for pain control after outpatient urologic surgery
Trial: NCT02187094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01165021
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00540553
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00540553
Drug: GSK971086
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256865
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone is taken 3 times a day
Trial: NCT02256865
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel is applied once a day
Trial: NCT02256865
Drug: Placebo for hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for hydrocortisone
Trial: NCT02256865
Drug: Placebo for testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for testosterone
Trial: NCT00990860
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
Trial: NCT04574284
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT04307576
Drug: Omitted Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of IV Doxorubicin
Trial: NCT04307576
Drug: 6-tioguanine+Standard Maintenance Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
Trial: NCT03238092
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: testosterone gel daily during the late luteal phase.
Trial: NCT03238092
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral estradiol during the late luteal phase.
Trial: NCT01427569
Drug: IZN-6D4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
Trial: NCT01009801
Drug: doxorubicin-eluting beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Trial: NCT00408421
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00665496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT00165646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: once daily orally for 4 weeks
Trial: NCT03013322
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00255684
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00294502
Drug: Gentamycin/citrate, Minocycline/EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03650452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-935 placebo-matching tablets or mini-tablets.
Trial: NCT03257930
Drug: ethanol injection
RxNorm normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inject ethanol in cystic thyroid nodule and follow up until complete recovery
Trial: NCT01013909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of one dose daily by means of an metered dose
Trial: NCT02044159
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
Trial: NCT02713230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL normal saline as single-injection
Trial: NCT00162305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, Once daily, 14 days.
Trial: NCT02745223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
Trial: NCT00861367
Drug: transurethral surgery with or without aspirin
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 100mg once a day, transurethral surgery with or without aspirin
Trial: NCT03484923
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of PDR001 administered every 4 weeks intravenously
Trial: NCT03484923
Drug: LAG525
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of LAG525 administered every 4 weeks intravenously
Trial: NCT03484923
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of INC280 administered twice daily orally
Trial: NCT03484923
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of ACZ885 administered every 4 weeks subcutaneosuly
Trial: NCT03484923
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
Trial: NCT01617681
Drug: VAL489
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 3mg/kg oral solution
Trial: NCT03225924
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cycles of 21 days - 750 mg/m²
Trial: NCT02917187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT03225924
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cycles of 21 days - 50mg/m²
Trial: NCT02364206
Drug: LY2228820
FDA approved: no
EMA approved: no
PMDA approved: no